Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Oct 09, 2023 3:27pm
262 Views
Post# 35676090

Recent MRTX take over offer $5+ billion

Recent MRTX take over offer $5+ billion

Fair question, how does Onc compare to MRTX?
I use Onc web site as my reference point. As well as the details in various analyst reports.
So....!
Fair evaluation, also from MRTX web site.
I will ignore the screaming investors who paid more/ share than present offer on the table.
In that perspective, the deal is not final & additional bidders have cropped up.

so?

MRTX , has two phase 3 drugs, well in progress.
including one approved by FDA under fast track approval.
ONC, has one product. With two almost phase 3 ready.

in that view alone. Regardless of on- going share price.& potential final market of the products.
I'd say the upper limit of an Onc buyout would be $2.5 billion.
( argue either upside or down, just my opinion).

Pela, assuming they get accelerated approval, out of the PanCan results. And/ or exceptional results out of Goblet & the updated pancreatic numbers... they become (/potential), worth much more.

As of today, they have HUGE potential. Yet not as far along as is MRTX.
MRTX is an example. Pharma will pay $ Billions for a marketable product.
MTRX did already have two in place licensing " deals"
generally speaking from a B.D. Point of view MRTX , much more established.

Side note. All of MRTX products have medium to high side effects & toxicities.
Pela has minimal to zero.

Moving the lens further back.
I would love to be able to say ONC should be bought out for many billions.
And to see that happen next few weeks.

Seeing the pattern over & over. ( I agree not all), most buy outs are prefaced with strong partnerships.
Onc needs to get to thst phase first.

A business development deal with Roche going into phase 3, will certainly move the SP well into the analysts ranges of ($5- $15) ps.
last mid point being $6.85 ( usd).
From there & depending on the intensity of the panc results at ESMO, will determine the future opportunities.
keep in mind, the PanCan people have the ear if FDA & could easily move Pela into accelerated approval.
THEN , Onc has marketable product value.
right now they have great phase 2 data & fantastic potential.

Lowest Buyout?
One billion $ was stated years ago. They have moved much further ahead since then.
I think under present circumstances a $ billion buyout, would please most.
That being well north of $14/ ps CDN.
partership first.
happy thanksgiving 

 

<< Previous
Bullboard Posts
Next >>